Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

382
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
382
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

321
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
321
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

540
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
540
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

419
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
419
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
189

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decoding the complexity of intestinal immunity with spatial transcriptomics.

Current opinion in immunology·2026
Same author

Promoting intestinal regeneration without tumor risk in immune-mediated inflammatory diseases.

Trends in immunology·2026
Same author

Spatiotemporal analysis reveals distinct inflammatory programs underlying chronic colitis.

Immunity·2026
Same author

TNFα signaling in radiation-induced chronic bowel dysfunction suggests therapeutic potential for IBD biologics.

Molecular medicine (Cambridge, Mass.)·2026
Same author

Uncovering Immune Niches in Health and Disease Using Spatial Transcriptomics.

European journal of immunology·2026
Same author

IL-26 from innate lymphoid cells regulates early-life gut epithelial homeostasis by shaping microbiota composition.

The EMBO journal·2025

Related Experiment Video

Updated: Sep 10, 2025

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.7K

B cells in inflammatory bowel disease.

Francisca A Castillo1, Bianca C Kern1, Eduardo J Villablanca1

  • 1Division of Immunology and Respiratory Medicine, Department of Medicine, Solna, Karolinska Institutet and University Hospital, Stockholm 17176, Sweden; Center of Molecular Medicine, Stockholm 17176, Sweden.

Immunology Letters
|August 22, 2025
PubMed
Summary

B cells play a complex role in inflammatory bowel diseases (IBD), moving beyond the traditional T cell focus. Understanding these diverse B cell functions is key to developing targeted therapies for IBD.

Keywords:
AntibodiesB cellsInflammatory bowel diseasePlasma cellsTertiary lymphoid structures

More Related Videos

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.2K
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

16.8K

Related Experiment Videos

Last Updated: Sep 10, 2025

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.7K
Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.2K
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

16.8K

Area of Science:

  • Immunology
  • Gastroenterology
  • Cell Biology

Background:

  • Inflammatory bowel diseases (IBD) were historically viewed as T cell-mediated.
  • Emerging evidence highlights significant B cell involvement in chronic intestinal inflammation.
  • B cells normally support gut immune tolerance and mucosal health.

Purpose of the Study:

  • To review the evolving understanding of B cell roles in IBD pathogenesis.
  • To emphasize the need for selective therapeutic strategies targeting specific B cell subsets.
  • To explore the potential for precise immunotherapies based on B cell dynamics.

Main Methods:

  • Review of current scientific literature on B cell biology in IBD.
  • Analysis of experimental models demonstrating B cell functions in intestinal inflammation.
  • Discussion of clinical observations regarding B cell-targeted therapies.

Main Results:

  • The B cell compartment is significantly altered in IBD, with increased plasma cells and altered antibody responses.
  • Pro-inflammatory B cell subsets, like Sca1⁺PD-L1⁺ B cells, emerge during IBD.
  • Experimental models show both detrimental and beneficial roles for B cells in IBD.
  • Limited efficacy of broad B cell depletion therapies (e.g., rituximab) suggests complexity.

Conclusions:

  • B cells have a multifaceted role in IBD, acting as both pathogenic and regulatory players.
  • Selective therapies are needed to target harmful B cells while preserving beneficial ones.
  • Further research into the spatial, phenotypic, and temporal dynamics of intestinal B cells is crucial for developing effective IBD immunotherapies.